Orange Book product · Generic (ANDA)
ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN LACTOBIONATE
At a glance
Feb 14, 2022
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Feb 14, 2022
4 yr 5 mo ago
Today
Pharmaceutical detail
Active ingredient
ERYTHROMYCIN LACTOBIONATE
Strength
EQ 500MG BASE/VIAL
Dosage form
INJECTABLE
Route
INJECTION
TE code
AP
Application
ANDA 215290
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of ERYTHROMYCIN LACTOBIONATE
- 1986ERYTHROCINBrand (NDA)
NDA 050609 · HOSPIRA
- —ERYTHROCINBrand (NDA)
NDA 050182 · HOSPIRA
- 2024ERYTHROMYCIN LACTOBIONATEGeneric (ANDA)
ANDA 216761 · GLAND
- 2020ERYTHROMYCIN LACTOBIONATEGeneric (ANDA)
ANDA 211086 · EXELA PHARMA
- 1993ERYTHROMYCIN LACTOBIONATEGeneric (ANDA)
ANDA 063253 · TEVA PARENTERAL
- 1989ERYTHROMYCIN LACTOBIONATEGeneric (ANDA)
ANDA 062993 · BAXTER HLTHCARE
- 1988ERYTHROCINGeneric (ANDA)
ANDA 062586 · ABBOTT
- 1986ERYTHROMYCIN LACTOBIONATEGeneric (ANDA)
ANDA 062604 · ABRAXIS PHARM
- 1986ERYTHROCINGeneric (ANDA)
ANDA 062638 · HOSPIRA
- 1985ERYTHROMYCINGeneric (ANDA)
ANDA 062563 · ELKINS SINN
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
